Estimating individual lifetime benefit and bleeding risk of adding oral anticoagulation to aspirin for patients with stable cardiovascular disease: directions from COMPASS?

Monika Kozieł; Gregory Y H Lip

doi:10.1093/eurheartj/ehz517

Estimating individual lifetime benefit and bleeding risk of adding oral anticoagulation to aspirin for patients with stable cardiovascular disease: directions from COMPASS?

Monika Kozieł, Gregory Y H Lip

Research output: Contribution to journal › Comment/debate › Research › peer-review

4 Citations (Scopus)

Abstract

This editorial refers to 'Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial', by T. I. deVries et al., on page 3771. Published on behalf of the European Society of Cardiology. All rights reserved.

Original language	English
Journal	European Heart Journal
Volume	40
Issue number	46
Pages (from-to)	3779-3781
Number of pages	3
ISSN	0195-668X
DOIs	https://doi.org/10.1093/eurheartj/ehz517
Publication status	Published - 7 Dec 2019

Access to Document

10.1093/eurheartj/ehz517

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

@article{27b114dd527d4e328ea8fb9735b13678,

title = "Estimating individual lifetime benefit and bleeding risk of adding oral anticoagulation to aspirin for patients with stable cardiovascular disease: directions from COMPASS?",

abstract = "This editorial refers to 'Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial', by T. I. deVries et al., on page 3771. Published on behalf of the European Society of Cardiology. All rights reserved.",

author = "Monika Kozie{\l} and Lip, {Gregory Y H}",

year = "2019",

month = dec,

day = "7",

doi = "10.1093/eurheartj/ehz517",

language = "English",

volume = "40",

pages = "3779--3781",

journal = "European Heart Journal",

issn = "0195-668X",

publisher = "Oxford University Press",

number = "46",

}

TY - JOUR

T1 - Estimating individual lifetime benefit and bleeding risk of adding oral anticoagulation to aspirin for patients with stable cardiovascular disease

T2 - directions from COMPASS?

AU - Kozieł, Monika

AU - Lip, Gregory Y H

PY - 2019/12/7

Y1 - 2019/12/7

N2 - This editorial refers to 'Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial', by T. I. deVries et al., on page 3771. Published on behalf of the European Society of Cardiology. All rights reserved.

AB - This editorial refers to 'Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial', by T. I. deVries et al., on page 3771. Published on behalf of the European Society of Cardiology. All rights reserved.

UR - http://www.scopus.com/inward/record.url?scp=85076195189&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehz517

DO - 10.1093/eurheartj/ehz517

M3 - Comment/debate

C2 - 31504403

SN - 0195-668X

VL - 40

SP - 3779

EP - 3781

JO - European Heart Journal

JF - European Heart Journal

IS - 46

ER -

Estimating individual lifetime benefit and bleeding risk of adding oral anticoagulation to aspirin for patients with stable cardiovascular disease: directions from COMPASS?

Abstract

Access to Document

AUB Link

Other files and links

Fingerprint

Cite this